Literature DB >> 16035950

Porcine reproductive and respiratory syndrome (PRRS) virus-specific interferon-gamma(+) T-cell responses after PRRS virus infection or vaccination with an inactivated PRRS vaccine.

F Piras1, S Bollard, F Laval, F Joisel, G Reynaud, C Charreyre, C Andreoni, V Juillard.   

Abstract

Although field studies have found porcine reproductive and respiratory syndrome (PRRSV) inactivated vaccines to be beneficial in reducing losses linked to PRRSV infection, immune mechanisms induced by these vaccines need better understanding. In the study reported here, we examined the interferon-gamma(+) (IFNgamma(+)) PRRS-specific T cell responses induced after infection and vaccination with an inactivated PRRS vaccine. Autologous monocyte-derived dendritic cells loaded with the PRRSV P120 strain were used to re-stimulate ex vivo T cells that had been primed in vivo by either the virus or the vaccine, or both. Virus-specific IFNgamma(+) T cells were quantified by using a porcine IFNgamma- ELISpot assay. A specific but low live virus-induced response was observed between days 35 and 70 for most of the pigs tested, while a significant inactivated vaccine-induced PRRSV-specific IFNgamma(+) T-cell response was measured soon after vaccination. Moreover, we observed that vaccination of pre-challenged pigs clearly favoured the PRRSV-specific cell-mediated immunity primed by the live virus. To characterize further the nature of the PRRSV-specific T cells, the different T-cell subsets involved in PRRSV immunity were analyzed by flow cytometry. We showed that the inactivated vaccine was able to prime both CD4(+)CD8(int+) and CD8(high) virus-specific T cells and that CD4(+)CD8(int+) were preferentially recalled by the live virus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16035950     DOI: 10.1089/vim.2005.18.381

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  15 in total

1.  Evaluation of the new commercial recombinant chimeric subunit vaccine PRRSFREE in challenge with heterologous types 1 and 2 porcine reproductive and respiratory syndrome virus.

Authors:  Jiwoon Jeong; Changhoon Park; Kyuhyung Choi; Chanhee Chae
Journal:  Can J Vet Res       Date:  2017-01       Impact factor: 1.310

Review 2.  Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects.

Authors:  Wasin Charerntantanakul
Journal:  World J Virol       Date:  2012-02-12

3.  Effect of sow vaccination against porcine circovirus type 2 (PCV2) on virological profiles in herds with or without PCV2 systemic disease.

Authors:  Alfonso Lopez-Rodriguez; Jeroen Dewulf; Tom Meyns; Rubén Del-Pozo-Sacristán; Christine Andreoni; Anne Goubier; Ludivine Chapat; Catherine Charreyre; François Joisel; Dominiek Maes
Journal:  Can Vet J       Date:  2016-06       Impact factor: 1.008

4.  Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

Authors:  Taehwan Oh; Hanjin Kim; Kee Hwan Park; Jiwoon Jeong; Ikjae Kang; Siyeon Yang; Chanhee Chae
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

5.  Immunopotentiation of four natural adjuvants co-administered with a highly pathogenic porcine reproductive and respiratory syndrome virus glycoprotein 5 subunit.

Authors:  Jun Peng; Yanmei Yuan; Si Shen; Zhongxiang Niu; Yijun Du; Jiaqiang Wu; Jun Li; Jiang Yu; Tao Wang; Jinbao Wang
Journal:  Virus Genes       Date:  2016-02-08       Impact factor: 2.332

6.  The Non-structural Protein 5 and Matrix Protein Are Antigenic Targets of T Cell Immunity to Genotype 1 Porcine Reproductive and Respiratory Syndrome Viruses.

Authors:  Helen Mokhtar; Miriam Pedrera; Jean-Pierre Frossard; Lucia Biffar; Sabine E Hammer; Lise K Kvisgaard; Lars E Larsen; Graham R Stewart; Satyanarayana Somavarapu; Falko Steinbach; Simon P Graham
Journal:  Front Immunol       Date:  2016-02-16       Impact factor: 7.561

7.  Comparative evaluation of the efficacy of commercial and prototype PRRS subunit vaccines against an HP-PRRSV challenge.

Authors:  Do Tien Duy; Hanjin Kim; Jiwoon Jeong; Kee Hwan Park; Siyeon Yang; Taehwan Oh; Seeun Kim; Ikjae Kang; Chanhee Chae
Journal:  J Vet Med Sci       Date:  2018-07-18       Impact factor: 1.267

Review 8.  Key Gaps in the Knowledge of the Porcine Respiratory Reproductive Syndrome Virus (PRRSV).

Authors:  Sergio Montaner-Tarbes; Hernando A Del Portillo; María Montoya; Lorenzo Fraile
Journal:  Front Vet Sci       Date:  2019-02-20

9.  Dynamics and Differences in Systemic and Local Immune Responses After Vaccination With Inactivated and Live Commercial Vaccines and Subsequent Subclinical Infection With PRRS Virus.

Authors:  Miroslav Toman; Vladimir Celer; Lenka Kavanová; Lenka Levá; Jitka Frolichova; Petra Ondráčková; Hana Kudláčková; Kateřina Nechvátalová; Jiri Salat; Martin Faldyna
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

Review 10.  Improved Vaccine against PRRSV: Current Progress and Future Perspective.

Authors:  Yuchen Nan; Chunyan Wu; Guoqian Gu; Weiyao Sun; Yan-Jin Zhang; En-Min Zhou
Journal:  Front Microbiol       Date:  2017-08-28       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.